Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

Conclusions:
Analysis of pooled data from 20 clinical trials in patients with T2DM suggests that saxagliptin is not associated with an increased CV risk.

Source: Cardiovascular Diabetology - February 4, 2014 Category: Cardiology Authors: Nayyar IqbalArtist ParkerRobert FrederichMark DonovanBoaz Hirshberg Source Type: research